Profile data is unavailable for this security.
About the company
Palatin Technologies, Inc. is a biopharmaceutical company. The Company is engaged in developing medicines based on molecules that modulate the activity of the melanocortin receptor system. The Company’s product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical needs and commercial potential. Its new product development activities focus primarily on MC1r agonists, with the potential to treat inflammatory and autoimmune diseases, such as dry eye disease, which is also known as keratoconjunctivitis sicca, uveitis, diabetic retinopathy, and inflammatory bowel disease. It is also developing peptides that are active at more than one melanocortin receptor, and MC4r peptide and small molecule agonists with potential utility in obesity and metabolic-related disorders, including rare disease and orphan indications. Its product candidates include PL9643 for dry eye disease and PL8177 for the treatment of ulcerative colitis.
- Revenue in USD (TTM)8.85m
- Net income in USD-4.81m
- Incorporated1986
- Employees29.00
- LocationPalatin Technologies Inc4-B Cedar Brook DriveCedar Brook Corporate CenterCRANBURY 08512United StatesUSA
- Phone+1 (609) 495-2200
- Fax+1 (609) 495-2202
- Websitehttps://www.palatin.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AN2 Therapeutics Inc | 0.00 | -33.99m | 29.05m | 22.00 | -- | 0.4805 | -- | -- | -1.13 | -1.13 | 0.00 | 2.21 | 0.00 | -- | -- | 0.00 | -41.21 | -53.41 | -45.91 | -58.50 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 20.72 | -- | -- | -- |
| Rein Therapeutics Inc | 0.00 | -58.89m | 29.44m | 11.00 | -- | 23.76 | -- | -- | -2.63 | -2.63 | 0.00 | 1.84 | 0.00 | -- | -- | 0.00 | -74.57 | -64.62 | -80.38 | -71.24 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -299.71 | -- | -- | -- |
| Harvard Apparatus Regenertv Tchnlgy Inc | 743.00k | -6.53m | 29.53m | 8.00 | -- | 19.00 | -- | 39.75 | -0.4029 | -0.4029 | 0.0459 | 0.0905 | 0.1891 | 9.21 | 371.50 | 92,875.00 | -166.09 | -292.39 | -227.59 | -1,068.06 | 16.29 | -- | -878.20 | -6,677.86 | 1.83 | -- | 0.00 | -- | 317.48 | -- | 14.30 | -- | -- | -- |
| Dyadic International Inc | 3.34m | -7.35m | 30.04m | 6.00 | -- | 11.52 | -- | 8.99 | -0.2371 | -0.2371 | 0.1077 | 0.072 | 0.2974 | -- | 5.27 | 557,033.30 | -65.38 | -46.12 | -89.89 | -51.96 | 31.54 | 35.01 | -219.86 | -335.59 | -- | -34.44 | 0.6579 | -- | 20.58 | 15.77 | 14.51 | -- | -- | -- |
| Lantern Pharma Inc | 0.00 | -18.92m | 30.20m | 24.00 | -- | 3.11 | -- | -- | -1.75 | -1.75 | 0.00 | 0.8684 | 0.00 | -- | -- | 0.00 | -86.16 | -32.94 | -104.31 | -34.72 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -30.20 | -- | 17.11 | -- |
| Reviva Pharmaceuticals Holdings Inc | 0.00 | -22.76m | 30.45m | 14.00 | -- | 5.52 | -- | -- | -0.4722 | -0.4722 | 0.00 | 0.0472 | 0.00 | -- | -- | 0.00 | -207.23 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 23.79 | -- | -- | -- |
| Neurosense Therapeutics Ltd | 0.00 | -8.66m | 30.89m | 15.00 | -- | -- | -- | -- | -0.361 | -0.361 | 0.00 | -0.0211 | 0.00 | -- | -- | 0.00 | -491.23 | -145.64 | -- | -198.79 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -1.02 | -- | -15.59 | -- |
| Palatin Technologies Inc | 8.85m | -4.81m | 31.07m | 29.00 | -- | 42.71 | -- | 3.51 | -13.52 | -13.52 | 12.39 | 0.4073 | 1.47 | -- | -- | 305,087.90 | -79.90 | -79.95 | -- | -118.70 | 0.00 | 91.70 | -54.32 | -1,326.05 | -- | -- | 0.00 | -- | -100.00 | -- | 41.80 | -- | -- | -- |
| Tempest Therapeutics Inc | 0.00 | -36.05m | 31.14m | 24.00 | -- | 1.65 | -- | -- | -10.40 | -10.40 | 0.00 | 1.43 | 0.00 | -- | -- | 0.00 | -141.49 | -63.01 | -215.46 | -80.57 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -41.88 | -- | 1.85 | -- |
| Werewolf Therapeutics Inc | 0.00 | -72.84m | 31.73m | 39.00 | -- | 1.04 | -- | -- | -1.62 | -1.62 | 0.00 | 0.6264 | 0.00 | -- | -- | 0.00 | -66.32 | -33.10 | -76.84 | -36.81 | -- | -- | -- | -593.05 | -- | -54.29 | 0.4829 | -- | -90.55 | -- | -88.70 | -- | -0.919 | -- |
| Jasper Therapeutics Inc | 0.00 | -91.02m | 31.90m | 64.00 | -- | 2.76 | -- | -- | -5.90 | -5.90 | 0.00 | 0.4135 | 0.00 | -- | -- | 0.00 | -116.04 | -75.11 | -147.54 | -86.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -10.55 | -- | -- | -- |
| Atara Biotherapeutics Inc | 151.93m | 23.40m | 32.09m | 38.00 | 2.03 | -- | 1.21 | 0.2112 | 2.19 | 2.19 | 12.81 | -5.08 | 1.76 | 3.99 | 93.55 | 993,006.60 | 27.07 | -67.79 | -- | -93.07 | 81.63 | -- | 15.40 | -558.47 | 1.02 | 15.24 | 8.31 | -- | 1,404.02 | -- | 69.07 | -- | -46.73 | -- |
| Onkure Therapeutics Inc | 0.00 | -81.21m | 32.79m | 46.00 | -- | 0.4936 | -- | -- | -12.78 | -12.78 | 0.00 | 4.90 | 0.00 | -- | -- | 0.00 | -107.93 | -48.73 | -115.20 | -53.34 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 31.94 | -- | 49.34 | -- |
| Promis Neurosciences Inc | 0.00 | -29.28m | 32.82m | 6.00 | -- | 3.57 | -- | -- | -18.62 | -18.62 | 0.00 | 4.27 | 0.00 | -- | -- | -- | -127.41 | -85.65 | -188.18 | -145.08 | -- | -- | -- | -3,184,250.00 | -- | -- | 0.00 | -- | -- | -- | 121.03 | -- | -- | -- |
| Bioqual Inc | 46.54m | 453.25k | 33.55m | 108.00 | 74.02 | 0.938 | 12.22 | 0.7209 | 0.5068 | 0.5068 | 52.03 | 39.99 | 0.7111 | -- | 3.19 | -- | 0.6926 | 4.12 | 0.7745 | 4.83 | 12.85 | 16.15 | 0.974 | 4.03 | -- | -- | 0.00 | 32.81 | -16.60 | 1.06 | -316.79 | -- | -36.99 | -6.51 |
| Cell Source Inc | 0.00 | -6.57m | 34.03m | -- | -- | -- | -- | -- | -0.1613 | -0.1613 | 0.00 | -0.4379 | 0.00 | -- | -- | -- | -2,039.39 | -1,758.85 | -- | -- | -- | -- | -- | -- | -- | -3.74 | -- | -- | -- | -- | -3.55 | -- | -- | -- |
Data as of Feb 13 2026. Currency figures normalised to Palatin Technologies Inc's reporting currency: US Dollar USD
30.39%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Janus Henderson Investors US LLCas of 28 Nov 2025 | 170.10k | 9.99% |
| Logos Global Management LPas of 06 Nov 2025 | 140.00k | 8.22% |
| Point72 Asset Management LPas of 12 Nov 2025 | 115.00k | 6.75% |
| Morgan Stanley & Co. LLCas of 31 Dec 2025 | 27.05k | 1.59% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 18.98k | 1.12% |
| Geode Capital Management LLCas of 31 Dec 2025 | 17.71k | 1.04% |
| Jane Street Capital LLCas of 31 Dec 2025 | 10.77k | 0.63% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 8.77k | 0.52% |
| Bleichroeder LPas of 31 Dec 2025 | 7.80k | 0.46% |
| Vanguard Global Advisers LLCas of 31 Dec 2025 | 1.25k | 0.07% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
